Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics

Gritstone Oncology, Inc. (GRTS): $2.80

0.21 (+8.11%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add GRTS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#203 of 363

in industry

GRTS Price/Volume Stats

Current price $2.80 52-week high $3.33
Prev. close $2.59 52-week low $1.14
Day low $2.64 Volume 2,014,100
Day high $2.89 Avg. volume 2,029,860
50-day MA $2.46 Dividend yield N/A
200-day MA $2.02 Market Cap 274.58M

GRTS Stock Price Chart Interactive Chart >

GRTS POWR Grades

  • GRTS scores best on the Sentiment dimension, with a Sentiment rank ahead of 49.35% of US stocks.
  • The strongest trend for GRTS is in Stability, which has been heading down over the past 26 weeks.
  • GRTS's current lowest rank is in the Stability metric (where it is better than 4.74% of US stocks).

GRTS Stock Summary

  • Of note is the ratio of GRITSTONE BIO INC's sales and general administrative expense to its total operating expenses; only 6.63% of US stocks have a lower such ratio.
  • With a price/sales ratio of 18.84, GRITSTONE BIO INC has a higher such ratio than 94.09% of stocks in our set.
  • Revenue growth over the past 12 months for GRITSTONE BIO INC comes in at -45.46%, a number that bests merely 5.51% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GRITSTONE BIO INC are CARA, LIFE, CDTX, IGMS, and CKPT.
  • Visit GRTS's SEC page to see the company's official filings. To visit the company's web site, go to gritstonebio.com.

GRTS Valuation Summary

  • GRTS's EV/EBIT ratio is -1.9; this is 113.01% lower than that of the median Healthcare stock.
  • Over the past 64 months, GRTS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for GRTS.

Stock Date P/S P/B P/E EV/EBIT
GRTS 2023-12-29 19.0 2.6 -1.4 -1.9
GRTS 2023-12-28 19.2 2.7 -1.4 -1.9
GRTS 2023-12-27 19.6 2.7 -1.4 -2.0
GRTS 2023-12-26 19.1 2.6 -1.4 -1.9
GRTS 2023-12-22 17.0 2.3 -1.2 -1.8
GRTS 2023-12-21 15.3 2.1 -1.1 -1.6

GRTS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GRTS has a Quality Grade of D, ranking ahead of 22.21% of graded US stocks.
  • GRTS's asset turnover comes in at 0.193 -- ranking 203rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows GRTS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.193 1 -0.623
2021-06-30 0.220 1 -0.671
2021-03-31 0.231 1 -0.816
2020-12-31 0.025 1 -1.309
2020-09-30 0.023 1 -1.050
2020-06-30 0.021 1 -1.011

GRTS Price Target

For more insight on analysts targets of GRTS, see our GRTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

Gritstone Oncology, Inc. (GRTS) Company Bio


Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.


GRTS Latest News Stream


Event/Time News Detail
Loading, please wait...

GRTS Latest Social Stream


Loading social stream, please wait...

View Full GRTS Social Stream

Latest GRTS News From Around the Web

Below are the latest news stories about GRITSTONE BIO INC that investors may wish to consider to help them evaluate GRTS as an investment opportunity.

Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved Drastically

Celebrations may be in order for Gritstone bio, Inc. ( NASDAQ:GRTS ) shareholders, with the analysts delivering a...

Yahoo | December 13, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted four employees nonqualified stock options to purchase an aggregate of 42,000 shares of its common stock with an exercise price of $1.53, which is equal to the closing price of Gritstone’s common stock on December 1, 2023, th

Yahoo | December 7, 2023

Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation:

Yahoo | November 20, 2023

Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine Development

Advancements in COVID-19 and Cancer Vaccine Programs Amid Increased R&D Spending

Yahoo | November 8, 2023

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating samRNA candidate versus an approved COVID-19 vaccine -- -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating Gritstone’s personalized cancer vaccine (PCV), GRANITE, in first-line metastatic, microsatellite stable colorectal cancer (MSS-CRC) remain expected in 1

Yahoo | November 8, 2023

Read More 'GRTS' Stories Here

GRTS Price Returns

1-mo 2.56%
3-mo 37.25%
6-mo 62.79%
1-year 5.26%
3-year -71.63%
5-year -78.95%
YTD 37.25%
2023 -40.87%
2022 -73.17%
2021 226.40%
2020 -56.08%
2019 -41.94%

Continue Researching GRTS

Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:

Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!